- /
- Supported exchanges
- / NSE
- / THEMISMED.NSE
Themis Medicare Limited (THEMISMED NSE) stock market data APIs
Themis Medicare Limited Financial Data Overview
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) and formulations for use in various therapeutic areas, including anti-tuberculosis, anti-malarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition, anaesthesia, gynecology, and orthopedics. It also offers anti-inflammatory drugs and other drugs. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Themis Medicare Limited data using free add-ons & libraries
Get Themis Medicare Limited Fundamental Data
Themis Medicare Limited Fundamental data includes:
- Net Revenue: 4 055 M
- EBITDA: 490 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2017-02-14
- EPS/Forecast: 0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.